Skip to main content

Articles

Practice Management

PARP Inhibitors Least Cost-Effective as Maintenance Therapy in Advanced Ovarian Cancer

Practice Management

Next-Generation Sequencing More Cost-Effective and Faster Than Single-Gene Testing

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected

Prostate Cancer

With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men

Lung Cancer, Oncology

Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer See also Value-Based Care

Conference Highlights ASCO, Introduction

Precision Medicine and Immunotherapy Highlighted at ASCO 2018

Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation

LOXO-292 Highly Effective in RET-Positive Cancers

FDA Approvals, News & Updates - August 2018

Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer

Page 68 of 244
Results 671 - 680 of 2434